Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

39.56 +0.09 (+0.22%)
Streaming Delayed Price Updated: 1:20 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Looks Like M&A Week in 3 Different Sectors ↗
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry. 
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
Via MarketMinute
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience ↗
In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days. While... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Wall Street Ends a Rough Quarter With Its Best Day, Iran Hope Ignites the Rally ↗
Via Chartmill
News headline image
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Centessa Stock Soared Today ↗
A pharma giant wants to buy the innovative drug developer. 
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY).... 
Via Finterra
Topics Economy Intellectual Property
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗
One of these is not like the other. 
Via The Motley Fool
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline. 
Via The Motley Fool
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally ↗
Centessa Pharmaceuticals develops therapies for rare and serious diseases, advancing a pipeline of clinical-stage and emerging candidates. 
Via The Motley Fool
Topics ETFs
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
A full exit during a volatile stretch raises a sharper question than timing alone. 
Via The Motley Fool
News headline image
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.